Russian biotech company obtains US patent for brand new cancer drug

Russian biotech company obtains US patent for brand new cancer drugOncoMax, a young Russian biotech developer, has obtained a US patent for its innovation monoclonal antibody for target cancer therapy.

OncoMax, a private Russian biotech developer, has obtained a US patent, US 8487083 dated July 16, 2013, for its II-RCA-01 monoclonal antibody specific to the FGFR1 fibroblast growth factor receptor, Russian Venture Company (RVC) announced. OncoMax was set up in 2010 with assistance from RVC to develop and launch new cancer drugs. The drug is designed to facilitate target therapy of oncology diseases. ?The US patent provides our company a fast track and advantage in introducing the product into the American market,? said Elina Zaveleva, the CEO of OncoMax. If the company successfully completes the current series of clinical trials, the drug will be approved for use as primary cancer medication and as a backup to reinforce other therapies that might work inefficiently. In addition to the latest US patent, OncoMax already has Russian and Eurasian Economic Community patents. The documents prove the company?s exclusive rights for the technology of inhibiting the FGFR1 for tumor proliferation prevention...